Skip to main navigation
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact
Clene Inc. Clene Inc.
  • About Us
    • Leadership
    • Board of Directors
  • Science
    • About CNM-Au8®
  • Pipeline
  • Patients
    • EAP
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • News
      • Events
    • Presentations
      • Investor Presentation
      • Scientific Posters & Presentations
      • Webinars
      • Publications
    • Corporate Governance
      • Executive Management
      • Board of Directors
      • Committee Composition
      • Governance Documents
    • Financial Information
      • SEC Filings
      • Annual Reports
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Analyst Coverage
    • Investor Resources
      • Investor FAQs
      • Information Request Form
      • Investor Email Alerts
  • Contact

News

Novel MS Drug Good as Gold in Phase II Study
Medpagetoday
April 25, 2023
Results of Clinical Trials for CNM-Au8, A Potential ALS Treatment: James Berry, MD, MPH
NeurologyLive
April 25, 2023
ALS drugmakers, encouraged by recent FDA feedback, set their sights on a key protein
Biopharma Dive
March 27, 2023
CNM-Au8 found to delay clinical worsening in ALS HEALEY trial
ALS News Today
March 10, 2023
ALS Advances and Hot Topics for MDA 2023: Matthew B. Harms, MD
NeurologyLive
March 9, 2023
CNM-Au8 Demonstrates Significant Survival Benefit in HEALEY-ALS Interim Analysis
NeurologyLive
March 9, 2023
Clene's Nanocrystal ALS treatment bounces back with positive data
BioSpace
March 9, 2023
MS New Notes: Briumvi, vitamin D, CNM-Au8
Multiple Sclerosis News Today
March 6, 2023
ACTRIMS 2023 – Michael Hotchkin, Chief Development Officer, Clene Inc.
Multiple Sclerosis News Today
February 27, 2023
CNM-Au8 Shows Positive Findings on MS-Related Biomarkers of Whole Brain, White Matter
NeurologyLive
February 14, 2023

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »


1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2023 Clene Nanomedicine, Inc. - All rights reserved